azomycin has been researched along with Carcinoma, Ductal, Pancreatic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brender, JR; Chandramouli, GVR; Kishimoto, S; Krishna, MC; Mitchell, JB; Saida, Y; Yamamoto, K | 1 |
| Andersen, LMK; Galappathi, K; Gaustad, JV; Hauge, A; Rofstad, EK; Simonsen, TG; Wegner, CS | 1 |
| Ahluwalia, D; Bhupathi, D; Hart, CP; Li, W; Liu, Q; Meng, F; Ruprell, AS; Sun, JD; Wang, Y | 1 |
| Dhani, NC; Gallinger, S; Hedley, DW; Hill, RP; Pintilie, M; Schwock, J; Serra, S; Xu, J | 1 |
2 trial(s) available for azomycin and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Xenograft Model Antitumor Assays | 2015 |
Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole.
Topics: Adult; Analysis of Variance; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Feasibility Studies; Female; Humans; Immunohistochemistry; Indicators and Reagents; Injections, Intravenous; Male; Nitroimidazoles; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Premedication; Selection Bias | 2015 |
2 other study(ies) available for azomycin and Carcinoma, Ductal, Pancreatic
| Article | Year |
|---|---|
Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; Mice; Neoplasms, Experimental; Nitroimidazoles; Oxidation-Reduction; Pancreatic Neoplasms; Phosphoramide Mustards; Prodrugs | 2021 |
Dynamic contrast-enhanced MRI of the microenvironment of pancreatic adenocarcinoma xenografts.
Topics: Animals; Carcinoma, Pancreatic Ductal; Contrast Media; Extracellular Fluid; Female; Heterocyclic Compounds; Heterografts; Humans; Hypoxia; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Neoplasm Transplantation; Nitroimidazoles; Organometallic Compounds; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Pressure; Tumor Microenvironment | 2017 |